This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Tropisetron

Well Researched

A serotonin-3 (5-HT3) antagonist marketed in EU/Asia as the chemotherapy anti-emetic Navoban that also acts as a partial agonist at the α7…

Aliases (6)

Navoban · Ictyl · Navogan · Setrovel · ICS-205-930 · Tropisetron HCl

TYPICAL DOSE

5 mg

Daily

ROUTE

Oral (tablet)

Oral

CYCLE

unstudied

As prescribed

STORAGE

Room temp; original container

Room temp

Overview

What is Tropisetron?

Tropisetron is a 5-HT3 receptor antagonist used outside the US (not FDA-approved) for chemotherapy-induced nausea and vomiting (CINV). Beyond its antiemetic role, it has gained nootropic interest as a partial agonist at the alpha-7 nicotinic acetylcholine receptor (α7 nAChR).

Key Benefits

Prevents chemotherapy-induced and post-operative nausea/vomiting, may improve cognition (especially in schizophrenia and Alzheimer's) via α7 nAChR partial agonism, and shows anti-inflammatory and analgesic effects.

Mechanism of Action

Antagonizes 5-HT3 (serotonin-3) receptors, blocking the vagal/CNS emetic reflex driven by chemotherapy. Separately, partial agonism at the α7 nicotinic acetylcholine receptor enhances cholinergic signaling implicated in attention, memory, and cholinergic anti-inflammatory pathway.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

▸Brand options6 known

NavobanIctylNavoganSetrovelICS-205-930Tropisetron HCl

StatusUS — **NOT FDA-approved** (no US marketing; no DEA schedule; access requires research-chem channels or international pharmacy import). EU — Rx (Sandoz "Navoban" historically, withdrawn from many EU markets but still available via specialty pharmacies; Eastern Europe still actively prescribed). Japan/Korea/China — Rx anti-emetic, generics available. Australia — Rx, on PBS for chemotherapy-induced N/V.

Peptide Interactions

citicoline

Synergistic

(the canonical stack): Mechanistically interesting — citicoline raises synaptic ACh / choline pool, which is the natural agonist for α7 nAChR. Tropisetron's …

alpha-GPC

Synergistic

(planned PRN): same logic as citicoline, stronger acute effect.

galantamine

Synergistic

(1-2× monthly PRN if the user ever pursues lucid dreaming): Mechanistic stack: galantamine sensitizes α7 to ACh allosterically; tropisetron directly partial-…

modafinil

Synergistic

(V5 plan): No specific synergy on α7. Modafinil's wake/cognitive effect is largely orthogonal. Acceptable co-administration if both pursued.

Other 5-HT3 antagonists (ondansetron, granisetron, palonosetron):

Avoid

Additive 5-HT3 blockade + additive QT prolongation. Pointless and risky.

QT-prolonging drugs:

Avoid

macrolide antibiotics (azithromycin, clarithromycin, erythromycin), fluoroquinolones (especially moxifloxacin), antifungals (ketoconazole, fluconazole), some…

CYP2D6 inhibitors:

Avoid

paroxetine, fluoxetine, bupropion (the last is on the canonical stack optional list — relevant interaction). Paroxetine + tropisetron → tropisetron AUC 2-3× …

Strong serotonergic agents:

Avoid

SSRIs, SNRIs, MAO inhibitors at high doses — serotonin syndrome risk (low absolute risk, but documented).

α7 full agonists / experimental cognitive enhancers (encenicline, TAK-071, ABT-107 etc.):

Avoid

Additive α7 modulation; theoretically would compete or saturate. Not relevant for users in this archetype since none of these are accessible.

Quality Indicators

✓

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed packaging from a licensed pharmacy.

Generic vs branded

Generics are usually fine but bioavailability can vary slightly; track if you switch.

✗

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

Onset
30-60 min; peak 1-2 hr.
Acute
dosing: similar to 5 mg — mostly silent. Cognitive effect develops over weeks, not acutely (similar to most cognition-modulating drugs at the receptor system…

Side Effects & Safety 9

Side Effects

1Headache — the #1 reported side effect, ~20-30% of users at 5-10 mg/day. Frontal, mild-moderate, often persistent across dosing. May be the dose-limiting factor for many users.
2Constipation — meaningful (10-15%). 5-HT3 antagonism slows GI transit; this is a class effect (ondansetron, granisetron also cause constipation). Can be problematic for athletes whose protein-heavy diets already trend toward constipation.
3Dizziness — 5-10%, mild.
4Asthenia / fatigue — 5-10%, usually mild.
5Diarrhea (paradoxically, in a minority of users — possibly off-target serotonergic).
6Abdominal pain / cramping.
7Hot flushes, mild flushing.
8Hypotension — mild, 1-3%.
9Mild liver enzyme elevation — usually transient; clinically irrelevant in absence of liver disease.

When to Stop

QT prolongation / cardiac arrhythmia — the 2014 EMA review documented a class signal across 5-HT3 antagonists at high IV doses, leading to dose reductions (ondansetron single IV doses capped, similar caution for tropisetron). At oral 5-10 mg, the cardiac signal is much smaller but non-zero, and additive with other QT-prolonging drugs (some antibiotics, antifungals, antipsychotics, methadone). Pre-existing long-QT syndrome is a contraindication.
Hypersensitivity reactions — rare; typical drug-allergy spectrum.
Seizures — extremely rare at therapeutic doses.
Serotonin syndrome — rare but documented when combined with SSRIs/SNRIs/MAOIs at high doses (the same class concern as ondansetron).
Severe constipation / bowel obstruction — rare at low doses but encenicline's phase III GI signal (severe colonic events) means this class deserves attention to severe GI symptoms.
First 1-2 weeks: headache + GI tolerance. If headache > 4/10 or persistent into week 2, stop.
First 4-6 weeks of any chronic 10 mg/day exploration: ECG monitoring is reasonable for QT (especially in CYP2D6 PMs or anyone on other QT-active drugs). Watch for unexplained palpitations.
Chronic use beyond 8 weeks: unstudied territory in healthy adults. No data on receptor desensitization, tolerance, or long-term safety in non-disease populations.